Hiroki Ikezawa

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.

First-In-Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck.

Journal: Cancer science

Published: December 16, 2025

Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results.

Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results.

Journal: JTO clinical and research reports

Published: August 29, 2025

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results.

Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results.

Journal: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Published: May 02, 2025

A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.

A Phase 1b Study of Lenvatinib plus Nivolumab in Patients with Unresectable Hepatocellular Carcinoma.

Journal: Liver cancer

Published: April 21, 2025

Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.

Tasurgratinib (E7090) for cholangiocarcinoma with fibroblast growth factor receptor 2 fusions/rearrangements: a multicenter, open-label, Phase 2 study.

Journal: Japanese journal of clinical oncology

Published: March 10, 2025

Lifecycle of an introduced Dollfustrema (Bucephalidae) trematode in the Tone River system, Japan.

Lifecycle of an introduced Dollfustrema (Bucephalidae) trematode in the Tone River system, Japan.

Journal: Journal of helminthology

Published: January 20, 2025

Multicenter observational study to characterize fibroblast growth factor receptor 2 fusions or rearrangements in patients with advanced/metastatic cholangiocarcinoma.

Multicenter observational study to characterize fibroblast growth factor receptor 2 fusions or rearrangements in patients with advanced/metastatic cholangiocarcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 21, 2024

Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.

Tasurgratinib in patients with cholangiocarcinoma or gastric cancer: Expansion part of the first-in-human phase I study.

Journal: Cancer science

Published: March 18, 2024

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 08, 2023

First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.

First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.

Journal: Cancer

Published: August 23, 2022

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.

Journal: Cancer medicine

Published: August 15, 2022

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.

A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors.

Journal: Cancer chemotherapy and pharmacology

Published: January 26, 2022

Showing 1-12 of 24

Last Updated: 09/26/2026